Cargando…

Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis

BACKGROUND: The optimal timing of surgery after neoadjuvant chemotherapy (NAC) in patients with synchronous colorectal cancer liver metastases (SLM) remains controversial. We plan to analyze whether the choice of different surgical timings will have different effects on the perioperative and oncolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yaoqun, Wen, Ningyuan, Xiong, Xianze, Lu, Jiong, Li, Bei, Cheng, Nansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472641/
https://www.ncbi.nlm.nih.gov/pubmed/37658360
http://dx.doi.org/10.1186/s12957-023-03162-y
_version_ 1785100122400489472
author Wang, Yaoqun
Wen, Ningyuan
Xiong, Xianze
Lu, Jiong
Li, Bei
Cheng, Nansheng
author_facet Wang, Yaoqun
Wen, Ningyuan
Xiong, Xianze
Lu, Jiong
Li, Bei
Cheng, Nansheng
author_sort Wang, Yaoqun
collection PubMed
description BACKGROUND: The optimal timing of surgery after neoadjuvant chemotherapy (NAC) in patients with synchronous colorectal cancer liver metastases (SLM) remains controversial. We plan to analyze whether the choice of different surgical timings will have different effects on the perioperative and oncologic outcomes of patients. METHOD: We retrospectively collected all patients who met the inclusion and exclusion criteria from 2010 to 2020 in West China Hospital. Patients were grouped according to time interval (TI) after NAC to surgery. The perioperative and oncologic outcomes of the two groups were compared after propensity score matching. Univariate and multivariate analyzes were used to screen factors associated with prognosis. RESULT: Among 255 enrolled patients, 188 were matched with comparable baseline (94 each group). Patients in the 6≦TI≦8 group had longer operation time, less intraoperative blood loss, and less postoperative complications than those in the 4≦TI < 6 group. However, the overall survival (OS) (p = 0.012) and disease-free survival (DFS) (p = 0.013) of the patients in the 4≦TI < 6 group were better than those in the 6≦TI≦8 group. Subgroup analysis found that the above conclusions still apply in age ≥ 60, non-anemic patients, and patients who underwent R0 resection. OS was inversely correlated with TI in patients without preoperative jaundice. DFS was negatively correlated with TI in patients with preoperative jaundice. Multivariate analysis showed that the prolongation of TI after NAC to surgery was an independent prognostic risk factor for OS and DFS. CONCLUSIONS: Patients with SLM may be a better choice for surgery within 4–6 weeks after receiving NAC. Although patients with SLM undergoing surgery 4–6 weeks after NAC has a higher rate of postoperative complications, radical surgery is still recommended for a better survival benefit. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03162-y.
format Online
Article
Text
id pubmed-10472641
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104726412023-09-02 Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis Wang, Yaoqun Wen, Ningyuan Xiong, Xianze Lu, Jiong Li, Bei Cheng, Nansheng World J Surg Oncol Research BACKGROUND: The optimal timing of surgery after neoadjuvant chemotherapy (NAC) in patients with synchronous colorectal cancer liver metastases (SLM) remains controversial. We plan to analyze whether the choice of different surgical timings will have different effects on the perioperative and oncologic outcomes of patients. METHOD: We retrospectively collected all patients who met the inclusion and exclusion criteria from 2010 to 2020 in West China Hospital. Patients were grouped according to time interval (TI) after NAC to surgery. The perioperative and oncologic outcomes of the two groups were compared after propensity score matching. Univariate and multivariate analyzes were used to screen factors associated with prognosis. RESULT: Among 255 enrolled patients, 188 were matched with comparable baseline (94 each group). Patients in the 6≦TI≦8 group had longer operation time, less intraoperative blood loss, and less postoperative complications than those in the 4≦TI < 6 group. However, the overall survival (OS) (p = 0.012) and disease-free survival (DFS) (p = 0.013) of the patients in the 4≦TI < 6 group were better than those in the 6≦TI≦8 group. Subgroup analysis found that the above conclusions still apply in age ≥ 60, non-anemic patients, and patients who underwent R0 resection. OS was inversely correlated with TI in patients without preoperative jaundice. DFS was negatively correlated with TI in patients with preoperative jaundice. Multivariate analysis showed that the prolongation of TI after NAC to surgery was an independent prognostic risk factor for OS and DFS. CONCLUSIONS: Patients with SLM may be a better choice for surgery within 4–6 weeks after receiving NAC. Although patients with SLM undergoing surgery 4–6 weeks after NAC has a higher rate of postoperative complications, radical surgery is still recommended for a better survival benefit. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03162-y. BioMed Central 2023-09-01 /pmc/articles/PMC10472641/ /pubmed/37658360 http://dx.doi.org/10.1186/s12957-023-03162-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Yaoqun
Wen, Ningyuan
Xiong, Xianze
Lu, Jiong
Li, Bei
Cheng, Nansheng
Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis
title Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis
title_full Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis
title_fullStr Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis
title_full_unstemmed Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis
title_short Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis
title_sort timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472641/
https://www.ncbi.nlm.nih.gov/pubmed/37658360
http://dx.doi.org/10.1186/s12957-023-03162-y
work_keys_str_mv AT wangyaoqun timingofsurgeryinpatientswithsynchronouscolorectalcancerlivermetastasesundergoingneoadjuvantchemotherapyapropensityscoreanalysis
AT wenningyuan timingofsurgeryinpatientswithsynchronouscolorectalcancerlivermetastasesundergoingneoadjuvantchemotherapyapropensityscoreanalysis
AT xiongxianze timingofsurgeryinpatientswithsynchronouscolorectalcancerlivermetastasesundergoingneoadjuvantchemotherapyapropensityscoreanalysis
AT lujiong timingofsurgeryinpatientswithsynchronouscolorectalcancerlivermetastasesundergoingneoadjuvantchemotherapyapropensityscoreanalysis
AT libei timingofsurgeryinpatientswithsynchronouscolorectalcancerlivermetastasesundergoingneoadjuvantchemotherapyapropensityscoreanalysis
AT chengnansheng timingofsurgeryinpatientswithsynchronouscolorectalcancerlivermetastasesundergoingneoadjuvantchemotherapyapropensityscoreanalysis